BioPharma Ambition

ASCO urges industry to share real-world data for clinical trial efficiency

By Flora Southey

- Last updated on GMT

(Image: Getty/Bogdanhoda)
(Image: Getty/Bogdanhoda)
Sharing real-world data between CROs, sponsors and academic institutions will help improve trial design, says cancer association.

“Conventional clinical trials are becoming obsolete,” ​American Society of Clinical Oncology (ASCO) executive Richard Schilsky told delegates last month, arguing that an increasing number of cancer drugs and indications​ is forcing the industry to re-think clinical trials.

With more than 800 new cancer drugs in development – many of which target rare genotypes – it is no longer possible to conduct randomized clinical trials in every population, said Schilsky at the BioPharma Ambition Conference in Dublin, Ireland.

“We cannot learn everything that remains to be learned about all the various subtypes of cancer, by doing individual, prospective clinical trials about each subtype.

“We have to rethink the way we do clinical trials, in order to design clinical trials that are appropriate for the patient populations and the biology that we're trying to study,” ​he said. 

As a result, Schilsky urged delegates collect and share information over the entire lifecycle of the drug: “Learning needs to combine trial data and real-world data.”

The executive argued that firms do not need to know everything they eventually would like to know about a drug, at the time of market entry. While there is certain information required in order to justify market entry, there is a lot of information that can be developed about the drug in the post-market phase, he said.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

Related suppliers

Follow us

Products

View more

Webinars